Genotyping with prasugrel improved cost-effectiveness with an ICER of $35,800 per QALY compared to clopidogrel in patients with acute coronary syndrome undergoing PCI.
Does genotype-guided antiplatelet therapy or universal ticagrelor improve cost-effectiveness compared to generic clopidogrel in patients aged 65 years with ACS undergoing PCI?
Genotype-guided personalization of antiplatelet therapy with ticagrelor is cost-effective, but treating all patients with ticagrelor is also an economically reasonable alternative in some settings.
Effect estimate: ICER $35,800/QALY
Absolute Event Rate: 9.446% vs 9.428%
Genotype-guided personalization may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary intervention for ACS, but ticagrelor for all patients may bean economically reasonable alternative in some settings.
Kazi et al. (Mon,) conducted a other in Acute Coronary Syndrome (n=100,000). Prasugrel vs. Clopidogrel was evaluated on Quality-Adjusted Life-Years (QALYs) (ICER $35,800/QALY). Genotyping with prasugrel improved cost-effectiveness with an ICER of $35,800 per QALY compared to clopidogrel in patients with acute coronary syndrome undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: